WallStSmart

Coinbase Global Inc (COIN)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 809% more annual revenue ($62.58B vs $6.88B). COIN leads profitability with a 18.3% profit margin vs 12.4%. COIN appears more attractively valued with a PEG of 0.75. COIN earns a higher WallStSmart Score of 60/100 (C).

COIN

Buy

60

out of 100

Grade: C

Growth: 5.3Profit: 6.5Value: 9.3Quality: 7.0
Piotroski: 2/9Altman Z: 1.78

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

COINUndervalued (+26.4%)

Margin of Safety

+26.4%

Fair Value

$208.26

Current Price

$181.10

$27.16 discount

UndervaluedFair: $208.26Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COIN2 strengths · Avg: 8.0/10
PEG RatioValuation
0.758/10

Growing faster than its price suggests

Free Cash FlowQuality
$3.07B8/10

Generating 3.1B in free cash flow

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

COIN4 concerns · Avg: 3.3/10
EPS GrowthGrowth
4.3%4/10

4.3% earnings growth

Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
40.7x2/10

Premium valuation, high expectations priced in

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : COIN

The strongest argument for COIN centers on PEG Ratio, Free Cash Flow. Profitability is solid with margins at 18.3% and operating margin at 11.3%. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : COIN

The primary concerns for COIN are EPS Growth, Altman Z-Score, Piotroski F-Score. A P/E of 40.7x leaves little room for execution misses.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

COIN carries more volatility with a beta of 3.71 — expect wider price swings.

PFE is growing revenue faster at -1.2% — sustainability is the question.

PFE generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor FINANCIAL DATA & STOCK EXCHANGES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

COIN scores higher overall (60/100 vs 49/100), backed by strong 18.3% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coinbase Global Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

Coinbase Global, Inc. provides financial infrastructure and technology for the crypto economy. The company is headquartered in Wilmington, Delaware.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?